Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
124I-p5+14 PET/CT Imaging for Systemic Amyloidosis
NCT03678259Phase 2Completed
- Sponsor
- University of Tennessee Graduate School of Medicine
- Start
- Oct 2018
- Primary completion
- Oct 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 124I-evuzamitide in systemic amyloidosis, sponsored by University of Tennessee Graduate School of Medicine. Started Oct 2018; status: completed.
02
Drugs
124I-evuzamitide
03
Conditions
systemic amyloidosis
Beyond the preview
Go deeper on NCT03678259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03678259.